Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.52 |
| ▸ | IDO1 | P14902 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5054 | 0.97 | — | — | |
| SCHEMBL20465742 | 0.97 | — | — | |
| SCHEMBL30765100 | 0.97 | — | — | |
| SCHEMBL4441044 | 0.95 | TAAR1 (0.52) | TAAR1IDO1LMNAALDH1A1AOC3 | |
| Water SCHEMBL450787 | 0.95 | TAAR1 (0.52) | TAAR1IDO1LMNAALDH1A1AOC3 | |
| Benzene SCHEMBL28870609 | 0.95 | TAAR1 (0.52) | TAAR1IDO1LMNAALDH1A1AOC3 | |
| Benzyl Bromide SCHEMBL6043969 | 0.86 | ALDH1A1 (0.61) | TAAR1IDO1LMNAALDH1A1AOC3 | |
| Bicarbonate SCHEMBL16454532 | 0.83 | ALDH1A1 (0.43) | TAAR1IDO1LMNAALDH1A1KMT2A | |
| SCHEMBL7364761 | 0.83 | CYP3A4 (0.48) | TAAR1IDO1LMNAALDH1A1AOC3 | |
| Ether SCHEMBL453112 | 0.83 | IDO1 (0.44) | TAAR1IDO1LMNAALDH1A1AOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009066326-A2 | IMPROVED PROCESS FOR THE PREPARATION OF PRASUGREL AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | MSN LABORATORIES LIMITED (IN) | 2009-05-28 | — | — | WO | claimed |
| US-8394993-B2 | Process for the preparation of pharmaceutical intermediates | EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG (HU) | 2013-03-12 | — | — | US | disclosed |
| EP-2499147-A2 | IMPROVED PROCESSES FOR PREPARING PRASUGREL AND PHARMACEUTICALLY ACCEPTABLE SALTS THEROEOF | MSN Laboratories Limited (IN) | 2012-09-19 | — | — | EP | disclosed |
| US-20120202066-A1 | Processes For Preparing Prasugrel And Pharmaceutically Acceptable Salts Thereof | MSN LABORATORIES LIMITED (IN) | 2012-08-09 | — | — | US | disclosed |
| EP-2231575-B1 | PROCESS FOR THE PREPARATION OF PHARMACEUTICAL INTERMEDIATES | EGIS GYOGYSZERGYAR NYILVANOSAN MUEKOEDOE RESZVENYTARSASAG (HU) | 2011-06-22 | — | — | EP | disclosed |
| WO-2011042918-A2 | NOVEL AND IMPROVED PROCESSES FOR THE PREPARATION OF PRASUGREL, ITS INTERMEDIATES AND PHARMACEUTICALLY ACCEPTABLE SALTS | MSN LABORATORIES LIMITED (IN) | 2011-04-14 | — | — | WO | disclosed |
| EP-1966146-B1 | 4,5-DIHYDRO- (1H)-PYRAZOLE DERIVATIVES AS CANNABINOID CB1 RECEPTOR MODULATORS | ABBOTT HEALTHCARE PRODUCTS BV (NL) | 2011-03-02 | — | — | EP | disclosed |
| US-20100274020-A1 | PROCESS FOR THE PREPARATION OF PHARMACEUTICAL INTERMEDIATES | EGIS GYOGYSZERGYAR NYILVANOSAN MUKODO RESZVENYTARSASAG (HU) | 2010-10-28 | — | — | US | disclosed |
| EP-2231575-A2 | PROCESS FOR THE PREPARATION OF PHARMACEUTICAL INTERMEDIATES | Egis Gyógyszergyár Nyilvánosan Müködö Részvénytársaság (HU) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009068923-A2 | PROCESS FOR THE PREPARATION OF PHARMACEUTICAL INTERMEDIATES | EGIS GYÓGYSZERGYÁR NYILVÁNOSAN MŰKÖDŐ RÉSZVÉNYTÁRSASÁG (HU) | 2009-06-04 | — | — | WO | disclosed |
| WO-2009066326-A2 | IMPROVED PROCESS FOR THE PREPARATION OF PRASUGREL AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | MSN LABORATORIES LIMITED (IN) | 2009-05-28 | — | — | WO | disclosed |
| EP-1966146-A1 | 4,5-DIHYDRO- (1H)-PYRAZOLE DERIVATIVES AS CANNABINOID CB1 RECEPTOR MODULATORS | Solvay Pharmaceuticals B.V. (NL) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007071662-A1 | 4,5-DIHYDRO- (1H)-PYRAZOLE DERIVATIVES AS CANNABINOID CB1 RECEPTOR MODULATORS | SOLVAY PHARMACEUTICALS B.V. (NL) | 2007-06-28 | — | — | WO | disclosed |
| US-20070142362-A1 | 4,5-Dihydro-(1H)-pyrazole derivatives as cannabinoid CB1 receptor modulators | SOLVAY PHARMACEUTICALS B.V. | 2007-06-21 | — | — | US | disclosed |
| EP-0862568-A1 | SUBSTITUTED PIPERIDINE DERIVATIVES AS SELECTIVE AGONISTS OF 5-HT RECEPTORS | MERCK SHARP & DOHME LTD. (GB) | 1998-09-09 | — | — | EP | disclosed |
| WO-1997018202-A1 | SUBSTITUTED PIPERIDINE DERIVATIVES AS SELECTIVE AGONISTS OF 5-HT RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 1997-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142362-A1 | 4,5-Dihydro-(1H)-pyrazole derivatives as cannabinoid CB1 receptor modulators | CNR1, CNR2, GPR55 | TAAR1 278/4885IDO1 1895/4885LMNA 4320/4885 |
| US-20100274020-A1 | PROCESS FOR THE PREPARATION OF PHARMACEUTICAL INTERMEDIATES | PF4, F2, F3 | TAAR1 3966/4885IDO1 3637/4885LMNA 3000/4885 |
| US-20120202066-A1 | Processes For Preparing Prasugrel And Pharmaceutically Acceptable Salts Thereof | SF1, PFKP, CYP2F1 | TAAR1 3868/4885IDO1 3605/4885LMNA 3854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.